KalVista Pharmaceuticals Inc (KALV) concluded trading on Thursday at a closing price of $12.00, with 0.5 million shares of worth about $5.95 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.17% during that period and on April 17, 2025 the price saw a gain of about 2.17%. Currently the company’s common shares owned by public are about 49.49M shares, out of which, 38.56M shares are available for trading.
Stock saw a price change of 13.85% in past 5 days and over the past one month there was a price change of -0.83%. Year-to-date (YTD), KALV shares are showing a performance of 41.68% which increased to 1.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.30 but also hit the highest price of $15.50 during that period. The average intraday trading volume for KalVista Pharmaceuticals Inc shares is 552.96K. The stock is currently trading 3.82% above its 20-day simple moving average (SMA20), while that difference is up 7.02% for SMA50 and it goes to 8.36% higher than SMA200.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) currently have 49.49M outstanding shares and institutions hold larger chunk of about 89.05% of that.
The stock has a current market capitalization of $596.59M and its 3Y-monthly beta is at 0.08. It has posted earnings per share of -$3.73 in the same period. It has Quick Ratio of 10.44 while making debt-to-equity ratio of 0.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KALV, volatility over the week remained 6.17% while standing at 7.70% over the month.
Analysts are in expectations that KalVista Pharmaceuticals Inc (KALV) stock would likely to be making an EPS of -0.83 in the current quarter, while forecast for next quarter EPS is -0.95 and it is -2.96 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.95 which is -0.73 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.07 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -3.28% while it is estimated to increase by 16.52% in next year. EPS is likely to grow at an annualized rate of 20.85% for next 5-years, compared to annual growth of -20.06% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on January 31, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $19 to it. Coverage by TD Cowen stated KalVista Pharmaceuticals Inc (KALV) stock as a Buy in their note to investors on January 07, 2025, suggesting a price target of $30 for the stock. On December 18, 2024, BofA Securities Initiated their recommendations, while on June 15, 2020, H.C. Wainwright Initiated their ratings for the stock with a price target of $30. Stock get an Outperform rating from SVB Leerink on July 29, 2019.
